The promise of novel FolRα-targeting antibody
Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.
Source: eurekalert.org